SAB Biotherapeutics Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $1.27M Down From $3.59M YoY
Portfolio Pulse from Benzinga Newsdesk
SAB Biotherapeutics (NASDAQ:SABS) reported Q3 earnings with a loss of $(0.10) per share, surpassing the estimated $(0.12) per share. Despite the earnings beat, the company's sales declined to $1.27M from $3.59M in the same quarter last year, marking a 64.71% decrease.
November 14, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
SAB Biotherapeutics exceeded EPS estimates but experienced a significant decrease in sales compared to the previous year.
While SAB Biotherapeutics beat EPS estimates, which could be seen as a positive sign, the substantial decrease in sales year-over-year is likely to raise concerns among investors about the company's revenue growth and future profitability. The mixed results present both positive and negative aspects, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100